June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Assessing the usability of the ranibizumab 0.5 mg prefilled syringe (PFS) by healthcare professionals in the US
Author Affiliations & Notes
  • Andrew N Antoszyk
    Retina, Charlotte EEN&T Associates, Charlotte, North Carolina, United States
  • Carl W Baker
    Paducah Retinal Center, Paducah, Kentucky, United States
  • Howard Cummings
    Southeastern Retina Associates, Kingsport, Tennessee, United States
  • Jorge Calzada
    Charles Retina Institute, Germantown, Tennessee, United States
  • Joanna So
    Genentech, Inc., San Francisco, California, United States
  • Carlos Quezada-Ruiz
    Genentech, Inc., San Francisco, California, United States
  • Zdenka Haskova
    Genentech, Inc., San Francisco, California, United States
  • Footnotes
    Commercial Relationships   Andrew Antoszyk, DRCR.net (C), Opthea (C); Carl Baker, Allergan (C), Genentech (C); Howard Cummings, None; Jorge Calzada, Abbvie (C), Alcon (C), Genentech (C), Regeneron (C), RegenexBio (C); Joanna So, Genentech, Inc. (E); Carlos Quezada-Ruiz, Genentech, Inc. (E); Zdenka Haskova, Genentech, Inc. (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1953. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Andrew N Antoszyk, Carl W Baker, Howard Cummings, Jorge Calzada, Joanna So, Carlos Quezada-Ruiz, Zdenka Haskova; Assessing the usability of the ranibizumab 0.5 mg prefilled syringe (PFS) by healthcare professionals in the US. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1953.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The recently FDA-approved sterile ranibizumab PFS eliminates injection preparation steps, which in previous studies reduced procedure time compared with the standard vial, leading to improved office efficiency. The purpose of these studies was to evaluate the usability of the ranibizumab PFS by assessing whether US healthcare professionals could successfully prepare and perform intravitreal injections (IVI) using the ranibizumab PFS without prior training, and with only the Instructions for Use and US Prescribing Information available.

Methods : In a simulated-use usability study, ophthalmic medical personnel (n=15) prepared the ranibizumab PFS and retina specialists (n=15) performed injections into a model eye. In an actual-use usability study (ClinicalTrials.gov identifier: NCT02698566), medical assistants (n=3) prepared the PFS and retina specialists (n=3) performed IVI into the study eyes of patients with retinal disease (n=35). Twelve tasks specific to the unpacking, preparation, and proper administration of the PFS for IVI were evaluated by two study assessors. Task performances were evaluated for use errors, close calls, and operational difficulties. Post-injection subjective user evaluations were given to assess ease of use.

Results : All participants successfully performed all essential and safety-critical tasks without use errors in both the simulated-use and actual-use human factors usability studies. The majority of ranibizumab PFS users rated the tasks required to use the ranibizumab PFS as “Easy” or “Very Easy.” A single adverse event (AE) was observed, with 1 patient experiencing a mild subconjunctival hemorrhage that resolved by end of study. This AE was deemed related to the injection procedure and not to the PFS itself.

Conclusions : Both the simulated-use and actual-use usability studies yielded consistent data, showing that healthcare professionals are able to use the ranibizumab PFS by successfully performing all critical tasks involved in preparing and delivering an IVI while maintaining aseptic conditions and without prior training. Considering the number of patients that require IVI for retinal diseases, the ease-of-use, time savings achieved, and reduced risk of contamination associated with use of the ranibizumab PFS may represent a significant benefit for both health care providers and patients in real world clinical settings.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×